Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
8 hedge funds and large institutions have $711K invested in Aridis Pharmaceuticals Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
33% more funds holding
Funds holding: 6 → 8 (+2)
28% more capital invested
Capital invested by funds: $556K → $711K (+$155K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$92.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$9.31K |
| 3 |
Millennium Management
New York
|
+$5.54K |
| 4 |
FP
Financial Perspectives
Minneapolis,
Minnesota
|
+$1.73K |
| 5 |
JP Morgan Chase
New York
|
+$21 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$20.5K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $493K | – | – | – |
|
|
2
BlackRock
New York
| $131K | +$92.1K | +13,343 | +212% |
|
|
3
Millennium Management
New York
| $74K | +$5.54K | +802 | +8% |
|
|
4
UBS Group
Zurich,
Switzerland
| $9K | +$9.31K | +1,349 | New |
|
5
Wells Fargo
San Francisco,
California
| $2K | – | – | – |
|
|
FP
6
Financial Perspectives
Minneapolis,
Minnesota
| $1.66K | +$1.73K | +250 | New |
|
|
7
Bank of America
Charlotte,
North Carolina
| – | -$20.5K | -2,967 | -99% |
|
|
8
Victory Capital Management
San Antonio,
Texas
| – | -$12K | -2,068 | Closed |
|
|
9
JP Morgan Chase
New York
| – | +$21 | +3 | New |
|
ARDS Hedge Fund Activity: Q2 2020 in Review
8 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q2 2020, worth a combined $711K — up 28% from $556K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ARDS positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was BlackRock, adding an estimated $92.1K. The largest seller was Bank of America, cutting an estimated $20.5K.
- 8 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q2 2020, up from 6 in Q1 2020.
- Funds reported $711K of Aridis Pharmaceuticals Inc. Common Stock stock for Q2 2020, up 28% quarter-over-quarter.
- 3 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q2 2020 and 1 closed out, a net change of +2 holders.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q2 2020 was BlackRock, an estimated $92.1K added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q2 2020 was Bank of America, an estimated $20.5K sold.
Based on aggregated 13F filings for Q2 2020.